{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:11:21Z","timestamp":1762762281636,"version":"3.38.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"DOI":"10.7759\/cureus.80333","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T11:34:16Z","timestamp":1741606456000},"source":"Crossref","is-referenced-by-count":1,"title":["A Rare Intruder of the Liver: A Case of Undifferentiated Pleomorphic Sarcoma"],"prefix":"10.7759","author":[{"given":"Sidart","family":"Pradeep","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devine","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Cain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurva","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shovendra","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0388-4","article-title":"Cutaneous soft tissue tumors: how do we make sense of fibrous and \"fibrohistiocytic\" tumors with confusing names and similar appearances?","volume":"33","author":"Hornick JL","year":"2020","unstructured":"Hornick JL. Cutaneous soft tissue tumors: how do we make sense of fibrous and \"fibrohistiocytic\" tumors with confusing names and similar appearances?. Mod Pathol. 2020, 33:56-65. 10.1038\/s41379-019-0388-4","journal-title":"Mod Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers5010218","article-title":"Histologic and genetic advances in refining the diagnosis of \"undifferentiated pleomorphic sarcoma\"","volume":"5","author":"Kelleher FC","year":"2013","unstructured":"Kelleher FC, Viterbo A. Histologic and genetic advances in refining the diagnosis of \"undifferentiated pleomorphic sarcoma\". Cancers (Basel). 2013, 5:218-33. 10.3390\/cancers5010218","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3467","article-title":"Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: state of the art and perspectives","volume":"36","author":"Widemann BC","year":"2018","unstructured":"Widemann BC, Italiano A. Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: state of the art and perspectives. J Clin Oncol. 2018, 36:160-7. 10.1200\/JCO.2017.75.3467","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20825","article-title":"YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas","volume":"49","author":"H\u00e9lias-Rodzewicz Z","year":"2010","unstructured":"H\u00e9lias-Rodzewicz Z, P\u00e9rot G, Chibon F, et al.. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosomes Cancer. 2010, 49:1161-71. 10.1002\/gcc.20825","journal-title":"Genes Chromosomes Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081169","article-title":"The PTEN tumor suppressor gene in soft tissue sarcoma","volume":"11","author":"Stefano S","year":"2019","unstructured":"Stefano S, Giovanni S. The PTEN tumor suppressor gene in soft tissue sarcoma. Cancers (Basel). 2019, 11:1169. 10.3390\/cancers11081169","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31377","article-title":"Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway","volume":"117","author":"Matushansky I","year":"2007","unstructured":"Matushansky I, Hernando E, Socci ND, et al.. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest. 2007, 117:3248-57. 10.1172\/JCI31377","journal-title":"J Clin Invest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22239","article-title":"Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases","volume":"119","author":"Toro JR","year":"2006","unstructured":"Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer. 2006, 119:2922-30. 10.1002\/ijc.22239","journal-title":"Int J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4453-z","article-title":"Radiation-associated undifferentiated pleomorphic sarcoma is associated with worse clinical outcomes than sporadic lesions","volume":"22","author":"Dineen SP","year":"2015","unstructured":"Dineen SP, Roland CL, Feig R, et al.. Radiation-associated undifferentiated pleomorphic sarcoma is associated with worse clinical outcomes than sporadic lesions. Ann Surg Oncol. 2015, 22:3913-20. 10.1245\/s10434-015-4453-z","journal-title":"Ann Surg Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.013","article-title":"Malignant fibrous histiocytoma: changing perceptions and management challenges","volume":"67","author":"Henderson MT","year":"2012","unstructured":"Henderson MT, Hollmig ST. Malignant fibrous histiocytoma: changing perceptions and management challenges. J Am Acad Dermatol. 2012, 67:1335-41. 10.1016\/j.jaad.2012.04.013","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-10-2","article-title":"Clinical characteristics of the primary hepatic malignant fibrous histiocytoma in China: case report and review of the literature","volume":"10","author":"Yao D","year":"2012","unstructured":"Yao D, Dai C. Clinical characteristics of the primary hepatic malignant fibrous histiocytoma in China: case report and review of the literature. World J Surg Oncol. 2012, 10:2. 10.1186\/1477-7819-10-2","journal-title":"World J Surg Oncol"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1136\/gut.28.6.668","article-title":"Hepatic sarcomas in adults: a review of 25 cases","volume":"28","author":"Forbes A","year":"1987","unstructured":"Forbes A, Portmann B, Johnson P, Williams R. Hepatic sarcomas in adults: a review of 25 cases. Gut. 1987, 28:668-74.","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S226896","article-title":"Undifferentiated pleomorphic sarcoma: long-term follow-up from a large institution","volume":"11","author":"Chen S","year":"2019","unstructured":"Chen S, Huang W, Luo P, et al.. Undifferentiated pleomorphic sarcoma: long-term follow-up from a large institution. Cancer Manag Res. 2019, 11:10001-9. 10.2147\/CMAR.S226896","journal-title":"Cancer Manag Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1586\/era.09.76","article-title":"MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st century","volume":"9","author":"Matushansky I","year":"2009","unstructured":"Matushansky I, Charytonowicz E, Mills J, Siddiqi S, Hricik T, Cordon-Cardo C. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st century. Expert Rev Anticancer Ther. 2009, 9:1135-44. 10.1586\/era.09.76","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02289.x","article-title":"Classification of pleomorphic sarcomas: where are we now?","volume":"48","author":"Dei Tos AP","year":"2006","unstructured":"Dei Tos AP. Classification of pleomorphic sarcomas: where are we now?. Histopathology. 2006, 48:51-62. 10.1111\/j.1365-2559.2005.02289.x","journal-title":"Histopathology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.174","article-title":"An approach to pleomorphic sarcomas: can we subclassify, and does it matter?","volume":"27","author":"Goldblum JR","year":"2014","unstructured":"Goldblum JR. An approach to pleomorphic sarcomas: can we subclassify, and does it matter?. Mod Pathol. 2014, 27:S39-46. 10.1038\/modpathol.2013.174","journal-title":"Mod Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20972","article-title":"Diagnosis and management of pleomorphic sarcomas (so-called \"MFH\") in adults","volume":"97","author":"Nascimento AF","year":"2008","unstructured":"Nascimento AF, Raut CP. Diagnosis and management of pleomorphic sarcomas (so-called \"MFH\") in adults. J Surg Oncol. 2008, 97:330-9. 10.1002\/jso.20972","journal-title":"J Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02284.x","article-title":"The evolving classification of soft tissue tumours: an update based on the new WHO classification","volume":"48","author":"Fletcher CD","year":"2006","unstructured":"Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006, 48:3-12. 10.1111\/j.1365-2559.2005.02284.x","journal-title":"Histopathology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2018.10.006","article-title":"Subclassification of pleomorphic sarcomas: how and why should we care?","volume":"37","author":"Hornick JL","year":"2018","unstructured":"Hornick JL. Subclassification of pleomorphic sarcomas: how and why should we care?. Ann Diagn Pathol. 2018, 37:118-24. 10.1016\/j.anndiagpath.2018.10.006","journal-title":"Ann Diagn Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0058","article-title":"NCCN guidelines insights: soft tissue sarcoma, version 1.2021","volume":"18","author":"von Mehren M","year":"2020","unstructured":"von Mehren M, Kane JM, Bui MM, et al.. NCCN guidelines insights: soft tissue sarcoma, version 1.2021. J Natl Compr Canc Netw. 2020, 18:1604-12. 10.6004\/jnccn.2020.0058","journal-title":"J Natl Compr Canc Netw"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03289","article-title":"Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) sarcoma groups","volume":"38","author":"Gronchi A","year":"2020","unstructured":"Gronchi A, Palmerini E, Quagliuolo V, et al.. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) sarcoma groups. J Clin Oncol. 2020, 38:2178-86. 10.1200\/JCO.19.03289","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1014859","article-title":"Case report: undifferentiated sarcoma with multiple tumors involved in Lynch syndrome: Unexpected favorable outcome to sintilimab combined with chemotherapy","volume":"12","author":"Liu J","year":"2022","unstructured":"Liu J, Chang X, Xiao G, et al.. Case report: undifferentiated sarcoma with multiple tumors involved in Lynch syndrome: Unexpected favorable outcome to sintilimab combined with chemotherapy. Front Oncol. 2022, 12:1014859. 10.3389\/fonc.2022.1014859","journal-title":"Front Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31517","article-title":"Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma","volume":"124","author":"Wisdom AJ","year":"2018","unstructured":"Wisdom AJ, Mowery YM, Riedel RF, Kirsch DG. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer. 2018, 124:3819-29. 10.1002\/cncr.31517","journal-title":"Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23111","article-title":"Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth","volume":"58","author":"Tokumoto H","year":"2019","unstructured":"Tokumoto H, Setoguchi T, Saitoh Y, et al.. Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth. Mol Carcinog. 2019, 58:2230-40. 10.1002\/mc.23111","journal-title":"Mol Carcinog"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1373230","article-title":"Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma","volume":"18","author":"May CD","year":"2017","unstructured":"May CD, Landers SM, Bolshakov S, et al.. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther. 2017, 18:816-26. 10.1080\/15384047.2017.1373230","journal-title":"Cancer Biol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336908-a-rare-intruder-of-the-liver-a-case-of-undifferentiated-pleomorphic-sarcoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T11:34:18Z","timestamp":1741606458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336908-a-rare-intruder-of-the-liver-a-case-of-undifferentiated-pleomorphic-sarcoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.80333","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,10]]}}}